SavedAdd your journal

Journals / Eurasian Journal of Toxicology / 2024 / Volume: 6 Issue: 3

Botulism: Clinical Features, Laboratory Insights and Management Options

Handan Çiftçi(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, BURSA YÜKSEK İHTİSAS SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-2471-4350
Ömer Çanacık(DOKUZ EYLUL UNIVERSITY)0000-0001-9346-7416
Pages
—
Publication Date
2024-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment includes supportive care, intubation, and early administration of botulinum antitoxin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Botulism is a neuroparalytic disease caused by the neurotoxin produced by Clostridium botulinum (a gram-positive, anaerobic, endospore-forming bacillus).
📊
Key Findings & Data:Botulinum neurotoxin (BoNT) is one of the most potent substance known, and seven toxin serotypes (serotypes A–G) have been identified.
💡
Conclusion & Impact:Treatment includes supportive care, intubation, and early administration of botulinum antitoxin.
🔬Design:Review
📍Scope:Comprehensive Sample
⚙️Variables:Botulism · toxicity · epidemic

Abstract

Botulism is a neuroparalytic disease caused by the neurotoxin produced by Clostridium botulinum (a gram-positive, anaerobic, endospore-forming bacillus). Botulinum neurotoxin (BoNT) is one of the most potent substance known, and seven toxin serotypes (serotypes A–G) have been identified. Type A serotype botulism is the most common cause of human botulism, and can occur in epidemics. Botulism occurs ingestion of food contaminated with BoNT, colonization of a wound by neurotoxin-producing Clostridium species, exposure to botulinum neurotoxins by inhalation or injection. All forms of botulism, progressive muscle weakness is usually seen, begins in the cranial nerves and progressing from proximal to distal to the extremities. This descending paralysis can lead to respiratory failure and death with involvement of the respiratory muscles. Treatment includes supportive care, intubation, and early administration of botulinum antitoxin.

🔖

Cite This Article

Çiftçi, H., Çanacık, Ö. (2024). Botulism: Clinical Features, Laboratory Insights and Management Options. Eurasian Journal of Toxicology, Volume: 6 Issue: 3. https://doi.org/10.51262/ejtox.1593433

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (33)

  1. Chatham-Stephens K, Fleck-Derderian S, Johnson SD, Sobel J, Rao AK, Meaney-Delman D. Clinical features of foodborne and wound botulism: a systematic review of the literature, 1932–2015. Clinical Infectious Diseases. 2018; 66(suppl_1):11-6. https://doi.org/10.1093/cid/cix811
  2. Rawson AM, Dempster AW, Humphreys C M, Minton NP. Pathogenicity and virulence of Clostridium botulinum. Virulence. 2023;14(1): 2205251. https://doi.org/10. 1080/21505594.2023.2205251
  3. Sobel J. Chapter 5 Botulism. In: Lutwick LI, Lutwick SM, editors. Beyond Anthrax, The Weaponization Of İnfectious Disease, Humana Press. 2009.p.85–105. https://doi. org/10.1007/978-1-59745-326-4_5
  4. Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster medicine and public health preparedness. 2007;1(2);122-34. https://doi.org/10.1097/ DMP.0b013e318158c5fd
  5. Lund BM, Peck MW. Clostridium botulinum. In: Guide to Foodborne Pathogens, 2nd ed.; Labbé RG, García S, editors.John Wiley & Sons Ltd.: Chichester, UK. 2013; pp. 91–111. https://doi.org/10.1002/9781118684856.ch6
  6. Caleo M, Restani L. Exploiting botulinum neurotoxins for the study of brain physiology and pathology. Toxins. 2018; 10(5); 175. https://doi.org/10.3390/toxins10050175
  7. Fleck-Derderian S, Shankar M, Rao AK, Chatham-Stephens K, Adjei S, Sobel J, Pillai S K. The epidemiology of foodborne botulism outbreaks: a systematic review. Clinical infectious diseases. 2018;66(suppl_1):73-S81. https://doi.org/10.1093/ cid/cix846
  8. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000; 82(5); 427-446. https://doi.org/10.1016/S0300- 9084(00)00216-9
  9. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recommendations Rep. 2021;70(2):1-30.
  10. Rao AK, Lin NH, Griese SE, Chatham-Stephens K, Badell ML, Sobel, J. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks. Clinical Infectious Diseases. 2018;66(suppl_1), 38-42. https://doi. org/10.1093/cid/cix814
  11. Singh M, Fernández-Frackelton M. Section Twelve: Infectious Diseases, Chapter 118: Bacteria. In: Walls RM, Robert S, Hockberger R S, Gausche-Hill M, Erickson TB, Wilcox SR, editors. Rosen’s, Emergency Medicine: Concepts and Clinical Practise, 10th Edition, Elsevier: 2023. p. 1586-1609.
  12. Krebs W, Higgins T, Buckley M, Augustine JJ, Raetzke BD, Werman HA. Botulism outbreak in a regional community hospital: lessons learned in transfer and transport considerations. Prehospital emergency care. 2019;23(1);49-57. https://doi.org/10.1080/10903127.2018.1476636
  13. Sobel J. The Organism And Its Toxins. Clinical Infectious Diseases. 2005 Oct 15;41(8):1167-73. https://doi. org/10.1086/444507.
  14. Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(Pt 1):33- 43. https://doi.org/10.1093/brain/awt285. Epub 2013 Oct 26. PMID: 24163275.
  15. Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve. 2000 Jul;23(7):1137-44. https://doi.org/10.1002/1097- 4598(200007)23:7 3.0.co;2-7. PMID: 10883013.
  16. Maslanka SE, Solomon HM, Sharma S, Johnson EA. Chapter 32. Clostridium botulinum and its toxins. In: Salfinger Y, Tortorello ML, editors. Compendium of methods for the microbiological examination of foods: Washington, DC: American Public Health Association Press; 2013.p.1-11.
  17. Kalb SR, Baudys J, Wang D, Barr JR. Recommended mass spectrometry-based strategies to identify botulinum neurotoxincontaining samples. Toxins (Basel). 2015 May 19;7(5):1765- 78. https://doi.org/10.3390/toxins7051765. PMID: 25996606; PMCID: PMC4448173.
  18. Griese SE, Kisselburgh HM, Bartenfeld MT, Thomas E, Rao AK, Sobel J, Dziuban EJ. Pediatric Botulism and Use of Equine Botulinum Antitoxin in Children: A Systematic Review. Clin Infect Dis. 2017 Dec 27;66(suppl_1):17-29. https://doi. org/10.1093/cid/cix812. PMID: 29293924.
  19. Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol. 2008 Aug;8(4):229-37. https://doi.org/10.1136/pn.2008.152611. PMID: 18644909.
  20. Hughes RA, Bihari D. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry. 1993 Apr;56(4):334- 43. https://doi.org/10.1136/jnnp.56.4.334. PMID: 8482951; PMCID: PMC1014946.
  21. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001 Jun;58(6):893-8. https://doi. org/10.1001/archneur.58.6.893. PMID: 11405803.
  22. Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, Gu W, Clements J, Kim HJ, Rao AK. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. Clin Infect Dis. 2017 Dec 27;66(suppl_1):57-64. https://doi.org/10.1093/cid/cix816. PMID: 29293928; PMCID: PMC5866099.
  23. Botulism antitoxin heptavalent. (A, B, C, D, E, F, G)—(Equine) [package insert]. Gaithersburg, MD: Cangene Corporation (as Emergent Biosolutions); 2017. https://www.fda.gov/ media/85514/download
  24. Badell ML, Rimawi BH, Rao AK, Jamieson DJ, Rasmussen S, Meaney-Delman D. Botulism During Pregnancy and the Postpartum Period: A Systematic Review. Clin Infect Dis. 2017 Dec 27;66(suppl_1):30-S37. https://doi.org/10.1093/cid/ cix813. PMID: 29293925.
  25. Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother. 2003 Jan;37(1):127-31. https://doi.org/10.1345/ aph.1C034. PMID: 12503947.
  26. Lee JH, Lee SI, Chung CJ, Lee JH, Lee SC, Choi SR, Oh JN, Bae JY. The synergistic effect of gentamicin and clindamycin on rocuronium-induced neuromuscular blockade. Korean J Anesthesiol. 2013 Feb;64(2):143-51. https://doi.org/10.4097/ kjae.2013.64.2.143.
  27. Mazuet C, Dano J, Popoff MR, Créminon C, Volland H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One. 2010 Aug 26;5(8):e12416. https://doi.org/10.1371/journal.pone.0012416.
  28. Osterhoudt KC, Alpern ER, Durbin D, Nadel F, Henretig FM. Activated charcoal administration in a pediatric emergency department. Pediatr Emerg Care. 2004 Aug;20(8):493-8. https://doi.org/10.1097/01.pec.0000136064.14704.d1.
  29. Paterson DL, King MA, Boyle RS, Pond SM, Whitby M, Wright M, Henderson A. Severe botulism after eating homepreserved asparagus. Med J Aust. 1992 Aug 17;157(4):269-70. https://doi.org/10.5694/j.1326-5377.1992.tb137135.x. PMID: 1435446.
  30. Merz B, Bigalke H, Stoll G, Naumann M. Botulism type B presenting as pure autonomic dysfunction. Clin Auton Res. 2003 Oct;13(5):337-8. https://doi.org/10.1007/s10286-003- 0118-2. PMID: 14564656.
  31. Jenzer G, Mumenthaler M, Ludin HP, Robert F. Autonomic dysfunction in botulism B: a clinical report. Neurology. 1975 Feb;25(2):150-3. https://doi.org/10.1212/wnl.25.2.150.
  32. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167-93. https://doi.org/10.1146/annurev.pharmtox.44.101802.121554.
  33. Cohen RE, Anderson DL. Botulism: emotional impact on patient and family. J Psychosom Res. 1986;30(3):321-6. https://doi.org/10.1016/0022-3999(86)90009-7.